Bone Marrow – CDD 133

Bone Marrow – CDD 133

REX-003

We are also conducting clinical development with an additional bone marrow derived cellular therapy, REX-003, which is a cellular therapy product that has been enriched for cells expressing CD133. CD133 is a marker of early endothelial progenitor cell phenotype and therefore enrichment of these cells is expected to enhance the clinical efficacy of the product.